Chantix is a non-nicotine prescription medicine to help adults 18 and over stop smoking.
Pfizer said results from 14 clinical trials involving approximately 7,000 smokers played vital role for proving Chantix’s effectiveness and importance in quitting cigarette smoking.
Currently, Pfizer is in discussion with the US Food and Drug Administration (FDA) regarding a protocol for conducting a meta-analysis of its clinical trial data to help further investigation of the cardiovascular safety of Chantix.
Pfizer Medical Affairs vice-president Gail Cawkwell said Pfizer scientists and doctors continuously evaluate the benefits and risks of its medicines, including Chantix.
"The currently available safety data on Chantix, including a pooled analysis of clinical data in 7,375 people trying to quit smoking, do not support an increased cardiovascular risk associated with Chantix," Cawkwell said.